The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Brendan J. Popson - CJS Securities, Inc. - Analyst
: Sorry, we have a little power surge, I think I missed my first slot. So I just want to give a warm welcome to Paul, first off. And then I wanted to ask
on just with your -- the full year guidance for revenue, reiterating that. It seemed like sales this quarter were a little below what we had expected
and then you're calling for more normal seasonality going into Q2. So I guess can you just -- could you help us walk through the cadence on how
you get to that revenue guidance? It feels like you might -- you would need a bit more upside than normal in the back half or like a bit more
seasonality, if that makes sense, to recover to get to that range. So could you walk through the cadence on how you guys get there?
Question: Brendan J. Popson - CJS Securities, Inc. - Analyst
: Okay. And it sounds like some of that is obviously services because the product sales are kind of where you would expect them, but some of that
coming back in as a part of it, too.
Okay. Great. And then on -- I was looking at your adjusted EBITDA waterfall. Your COVID initiative costs were -- I think they were like $9 million last
quarter. And this quarter, they are $5 million, which obviously is going in the right direction. I just want to reiterate, you might have answered this
on previous calls. Is most of that costs just absenteeism with like positive tests? And then my other question is, do you have any thoughts on how
we could think about that costs in the next couple of quarters?
Question: Brendan J. Popson - CJS Securities, Inc. - Analyst
: Okay. So not much of those costs are repeating because it sounds like year-over-year, it's all -- well, were working against you, but obviously, that's
a positive thing.
|
